Effetti della Ketamina sulla Depressione resistente

News - author: guia - posted: 27-05-2020

CINP Max Hamilton Memorial Prize Awardee
- Dr. Mu-Hong Chen
We would like to present to you the CINP Max Hamilton Memorial Prize Awardee, Dr. Mu-Hong Chen.
Dr Mu-Hong Chen, M.D., Ph.D. graduated from Department of Medicine, National Yang-Ming University, Taiwan in 2006 and received his general psychiatric training between 2009 and 2013 and completed his child and adolescent psychiatric training in 2014.
His research career began in the first year (2009) of the resident training course and joined and completed the rTMS/TBS (theta burst stimulation) clinical trials (as the second author) for treatment-resistant depression (TRD) under Prof Tung-Ping Su’s and Prof Cheng Ta Li’s instructions (Brain. 2014 Jul;137(Pt 7):2088-98).
Since 2011, Dr Chen began the big data research using the Taiwan National Health Insurance Research Database and published several important and influential epidemiological studies in high-impact factor journals (i.e., molecular psychiatry 2018 Aug;23(8):1756-1763., Diabetes care 2017 May;40(5):e60, Psychother Psychosom. 2018;87(1):62-64, JAACAP 2018 Jan;57(1):48-53., and Eur Neuropsychopharmacol. 2016 Nov;26(11):1760-1767) as the first or corresponding authors under Prof Ya-Mei Bai’s instructions to date.
Since 2012, Dr Chen and Prof Su conducted the first low-dose ketamine infusion clinical trial for patients with TRD in Taiwan and Asian countries, and published the significant results in 2017 (Neuropsychopharmacology (2017) 42, 2482–2492). After the low-dose ketamine infusion study, Dr Chen further investigated how to maintain the anti-depressant/suicidal effects of low-dose ketamine infusion and reported that Dcycloserine could maintain the anti-suicidal effect of ketamine infusion for TRD (Neuropsychopharmacology. 2019 Nov;44(12):2112-2118.). He received his Ph.D. degree based on his ketamine and TRD studies under Prof Su’s instruction in 2019.
He not only reported the clinical findings of ketamine and TRD trials but also further attempted to elucidate the brain mechanisms of the rapid anti-depressant/suicidal effects of ketamine infusion using neuroimaging methods, including PET and MRI (J Affect Disord. 2019 Dec 1;259:15-20, J Affect Disord. 2018 Jan 1;225:709-714, Hum Brain Mapp. 2016 Mar;37(3):1080-90). His PET studies found that low-dose ketamine triggered a rapid activation (40mins) in prefrontal cortex (PFC), anterior cingulate cortex (ACC) and supplementary motor area (SMA), following by only ACC and SMA activation in the second day post-infusion. He hypothesized that PFC may serve as a kindler for the rapid antidepressant effect of ketamine infusion and ACC and SMA may contribute the lasting effect of ketamine infusion.
Since Autumn 2018, Dr Chen conducts the first low-dose ketamine infusion clinical trial for TRD patients with chronic or high suicidal ideation (item 10 of MADRS ≥ 4) in Taiwan. He wants to further elaborate the underlying mechanisms of the rapid antisuicidal effect of low-dose ketamine.
For Dr Chen’s research hard-working, he received WFSBP poster travel award in 2013, Taiwan- Japanese Young Scientist Award in 2014 and 2015, and Outstanding Research Award and Excellent Research Award for Asian College of Neuropsychopharmacology 2019. Dr Chen is also enthusiastic in the teaching and got the Clinical Teaching Excellence Physician Award, 2016, Taipei Veterans General Hospital.
Finally, Dr Chen is also a poet, won several literary awards, and published threepoetries, including Sailor’s diary, Quietness, and Gods and Monsters. He also works hard in LGBT mental health and promotes the LGBT psychoeducation for the medical students and psychiatrists. Fonte: A.J. Neuropsichicpharmacology.